Fundraising Fox
Abarceo Pharma
Malmö, SE · Founded 2017 · 10 employees on LinkedIn · 2 known investors
Find your way into Abarceo Pharma
Sign up to see every warm intro you have to Abarceo Pharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Abarceo Pharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Abarceo Pharma is a pre-clinical stage biotech developing a small molecule platform targeting mitochondrial dysfunction via the VDAC1 protein, with an initial focus on treatments for Type 2 Diabetes. A spin-out of Lund University Diabetes Center, it also aims at related mitochondrial conditions such as cardiovascular disease and Alzheimer's disease.
Founders & leadership
Abarceo Pharma was founded in 2017 by Claes Wollheim and Albert Salehi.
Investors · 2
How we know: LU Innovation's portfolio page · Not right? Tell us
How we know: funding news · Not right? Tell us
Frequently asked questions
- What does Abarceo Pharma do?
- Abarceo Pharma is a pre-clinical stage biotech developing a small molecule platform targeting mitochondrial dysfunction via the VDAC1 protein, with an initial focus on treatments for Type 2 Diabetes. A spin-out of Lund University Diabetes Center, it also aims at related mitochondrial conditions such as cardiovascular disease and Alzheimer's disease.
- Who founded Abarceo Pharma?
- Abarceo Pharma was founded by Claes Wollheim, Albert Salehi in 2017.
- Who are Abarceo Pharma's investors?
- Abarceo Pharma's investors include LU Innovation, Almi Invest.
- Where is Abarceo Pharma headquartered?
- Abarceo Pharma is headquartered in Malmö, SE.